Last reviewed · How we verify

Matching placebo to Ramipril — Competitive Intelligence Brief

Matching placebo to Ramipril (Matching placebo to Ramipril) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Placebo (matching formulation for ACE inhibitor). Area: Cardiovascular.

marketed Placebo (matching formulation for ACE inhibitor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Matching placebo to Ramipril (Matching placebo to Ramipril) — Novartis. This is a matching placebo formulation designed to mimic Ramipril, an ACE inhibitor that lowers blood pressure by blocking angiotensin-converting enzyme.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Matching placebo to Ramipril TARGET Matching placebo to Ramipril Novartis marketed Placebo (matching formulation for ACE inhibitor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Placebo (matching formulation for ACE inhibitor) class)

  1. Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Matching placebo to Ramipril — Competitive Intelligence Brief. https://druglandscape.com/ci/matching-placebo-to-ramipril. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: